Developing a Palladium(II) Agent to Overcome Multidrug Resistance and Metastasis of Liver Tumor by Targeted Multiacting on Tumor Cell, Inactivating Cancer-Associated Fibroblast and Activating Immune Response
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c01175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Ming Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources/Key Laboratory for Chemistry and Molecular Engineering of Medicin…. Hauptthemen laut MEDLINE: Liver Neoplasms, Drug Resistance, Neoplasm, Drug Resistance, Multiple, Palladium. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: Natural Science Foundation of Guangxi Zhuang Autonomous Region, National Natural Science Foundation of China.
Abstract (Originalsprache)
To targeted overcome the multidrug resistance (MDR) and metastasis of liver tumors, we proposed to develop a palladium (Pd) agent based on a specific residue of human serum albumin (HSA) for multiacting on tumor cell and other components in the tumor microenvironment. To this end, a series of Pd(II) 2-acetylpyridine thiosemicarbazone compounds were optimized to obtain a Pd(II) compound (5b) with significant cytotoxicity against HepG2/ADM cells. Subsequently, we constructed a HSA-5b complex delivery system and revealed the structural mechanism of HSA delivering 5b. Importantly, 5b/HSA-5b effectively inhibited the growth and metastasis of multidrug resistant liver tumors, and HSA enhanced the targeting ability of 5b and reduced its side effects in vivo. Furthermore, we confirmed the mechanisms of 5b/HSA-5b integrating to overcome MDR and metastasis of liver tumors: multiacting on cancer cell, activating immune response, and inactivating cancer-associated fibroblasts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources/Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Collaborative Innovatio…
- MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, Guangdong Basic Research Center of Excellence for Functional Molecular Engineering, School of Chemistry, Sun Yat-Sen University, Guangzhou 510006, PR China.
ORCID-Profile: Ming Jiang, Zhenlei Zhang, Feng Yang
Förderung
- Natural Science Foundation of Guangxi Zhuang Autonomous Region
- National Natural Science Foundation of China
Zitieren
APA
Jiang, M., Li, W., Liang, J., Pang, M., Li, S., Xu, G., Zhu, M., Liang, H., Zhang, Z., & Yang, F. (2024). Developing a Palladium(II) Agent to Overcome Multidrug Resistance and Metastasis of Liver Tumor by Targeted Multiacting on Tumor Cell, Inactivating Cancer-Associated Fibroblast and Activating Immune Response. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01175
Vancouver
Jiang M, Li W, Liang J, Pang M, Li S, Xu G, et al. Developing a Palladium(II) Agent to Overcome Multidrug Resistance and Metastasis of Liver Tumor by Targeted Multiacting on Tumor Cell, Inactivating Cancer-Associated Fibroblast and Activating Immune Response. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01175
BibTeX
@article{Jiang2024,
author = {Jiang, Ming and Li, Wenjuan and Liang, Jinzhe and Pang, Min and Li, Shanhe and Xu, Gang and Zhu, Minghui and Liang, Hong and Zhang, Zhenlei and Yang, Feng},
title = {Developing a Palladium(II) Agent to Overcome Multidrug Resistance and Metastasis of Liver Tumor by Targeted Multiacting on Tumor Cell, Inactivating Cancer-Associated Fibroblast and Activating Immune Response},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c01175}
}
EUVIMED